CTI BioPharma to Present at Upcoming November Conferences

Rhea-AI Summary

CTI BioPharma Corp. (NASDAQ: CTIC) announced its management will present at two upcoming investor conferences in November 2022. The Stifel Healthcare Conference is scheduled for November 15, 2022, at 1:15 p.m. ET, while the Jefferies London Healthcare Conference will take place on November 17, 2022, at 10:50 a.m. ET and 3:50 p.m. GMT. Both presentations will be webcast live and available for replay on CTI BioPharma's website.

CTI focuses on developing targeted therapies for blood-related cancers, including its FDA-approved product, VONJO^®, for treating myelofibrosis.

SEATTLE, Nov. 8, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at two upcoming investor conferences in New York and London.

Presentation details:

Event: Stifel Healthcare Conference
Date: Tuesday, November 15, 2022
Time: 1:15 p.m. ET

Event: Jefferies London Healthcare Conference
Date: Thursday, November 17, 2022
Time: 10:50 a.m. ET/3:50 p.m. GMT

Both presentations will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ctibiopharma.com.

About CTI BioPharma Corp.

We are a commercial biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product, VONJO^® (pacritinib), a JAK2 and IRAK1 inhibitor, that spares JAK1. VONJO is approved for the treatment of adults with intermediate- or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10⁹/L. This indication is approved under FDA accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement.

VONJO^® is a registered trademark of CTI BioPharma Corp.

CTI BioPharma Investor Contacts:
Argot Partners
+212-600-1902
cti@argotpartners.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cti-biopharma-to-present-at-upcoming-november-conferences-301671331.html

SOURCE CTI BioPharma Corp.

FAQ

What is CTI BioPharma's stock symbol?

CTI BioPharma's stock symbol is CTIC.

When will CTI BioPharma present at the Stifel Healthcare Conference?

CTI BioPharma will present at the Stifel Healthcare Conference on November 15, 2022, at 1:15 p.m. ET.

What is the date and time for CTI BioPharma's presentation at the Jefferies London Healthcare Conference?

CTI BioPharma's presentation at the Jefferies London Healthcare Conference is on November 17, 2022, at 10:50 a.m. ET / 3:50 p.m. GMT.

Where can I watch the CTI BioPharma conference presentations?

The presentations can be watched live and replayed on CTI BioPharma's website in the Investors section.

What is VONJO and its significance for CTI BioPharma?

VONJO^® is CTI BioPharma's FDA-approved product for treating adults with myelofibrosis and is significant as it represents the company's focus on novel therapies for blood-related cancers.